- Home
- AMPY vs TNXP Comparison
AMPY vs TNXP Comparison
Compare AMPY & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPY
- TNXP
- Stock Information
- Founded
- AMPY 2011
- TNXP 2007
- Country
- AMPY United States
- TNXP United States
- Employees
- AMPY N/A
- TNXP N/A
- Industry
- AMPY Oil & Gas Production
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- AMPY Energy
- TNXP Health Care
- Exchange
- AMPY Nasdaq
- TNXP Nasdaq
- Market Cap
- AMPY 118.2M
- TNXP 118.2M
- IPO Year
- AMPY 2011
- TNXP N/A
- Fundamental
- Price
- AMPY $2.99
- TNXP $22.08
- Analyst Decision
- AMPY Strong Buy
- TNXP Strong Buy
- Analyst Count
- AMPY 2
- TNXP 2
- Target Price
- AMPY $10.25
- TNXP $585.00
- AVG Volume (30 Days)
- AMPY 1.3M
- TNXP 595.0K
- Earning Date
- AMPY 05-12-2025
- TNXP 05-12-2025
- Dividend Yield
- AMPY N/A
- TNXP N/A
- EPS Growth
- AMPY N/A
- TNXP N/A
- EPS
- AMPY 0.39
- TNXP N/A
- Revenue
- AMPY $290,431,100.00
- TNXP $10,041,000.00
- Revenue This Year
- AMPY $17.78
- TNXP $12.17
- Revenue Next Year
- AMPY $31.78
- TNXP $789.15
- P/E Ratio
- AMPY $8.14
- TNXP N/A
- Revenue Growth
- AMPY N/A
- TNXP N/A
- 52 Week Low
- AMPY $2.27
- TNXP $6.76
- 52 Week High
- AMPY $8.15
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- AMPY 51.72
- TNXP 64.64
- Support Level
- AMPY $2.60
- TNXP $18.45
- Resistance Level
- AMPY $3.25
- TNXP $19.94
- Average True Range (ATR)
- AMPY 0.23
- TNXP 1.62
- MACD
- AMPY 0.10
- TNXP 0.37
- Stochastic Oscillator
- AMPY 62.35
- TNXP 86.01
About AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.